Researchers determine the differential risk of dementia among men and women based on the presence of obstructive sleep apnea.

On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in ...

They first assessed binding of synthetic Aβ42 monomers conjugated to silica nanoparticles. Lecanemab had the highest sensitivity, detecting as little as 2 pM, while limit of detection (LoD) for ...

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report) today and set a price ...

Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker ...

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

Results from the open-label long-term extension study (OLE) following the core study of the lecanemab phase 3 Clarity AD study presented at AAIC in July, showed that the mean change from baseline ...

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...

Lipids Open the Door. Microglial cells treated with unlipidated (top) or lipidated (bottom) ApoE (yellow) along with fluorescently tagged Aβ (green). Lipidated ApoE was more readily internalized and ...

Those who drank less caffeine tended to have lower concentrations of a soluble form called Aβ42, with reduced ratios of Aβ42 with another form called Aβ40. They also had a reduced ratio between Aβ42 ...

Among all the enrolled studies, 10 studies reported plasma Aβ40 values, while 9 studies reported plasma Aβ42 values and 13 studies reported Aβ42/Aβ40 ratio. The pooled standardised mean difference ...